The flagship product is an oral, small molecule therapy that combines AMXT 1501, a proprietary polyamine uptake inhibitor, with DFMO (eflornithine), a polyamine synthesis inhibitor. This dual-agent approach works synergistically to significantly lower polyamine levels in cancer cells and the surrounding tumor microenvironment, which in turn suppresses myeloid-derived suppressor cells (MDSCs) and restores the innate immune system's ability to fight solid tumors.